RASONQUE
FDA-approved finished prescription medicine.
- Company
- Revolution Medicines, Inc.
- Context
- U.S. prescribing and product information
Terminology · current to 3 Sep 2026
RASONQUE, daraxonrasib and RMC-6236
Brand name, generic name and development code refer to the same active compound in different contexts. They do not make every material or supplier interchangeable.
The short answer
A naming map for researchers and procurement teams.
daraxonrasib
The nonproprietary name of the active ingredient.
- Context
- FDA records, scientific literature and compound identity
- CAS RN
- 2765081-21-6
RMC-6236
The identifier established during research and clinical development.
- Context
- Publications, trial registries and research catalogs
- Trial
- NCT05379985
RASolute 302
The pivotal study name, not a compound synonym.
- Registry
- NCT06625320
- Population
- Previously treated metastatic PDAC
FDA status
Daraxonrasib was approved on 26 August 2026.
The FDA identifies RASONQUE (daraxonrasib) as an inhibitor of the RAS GTPase family. The approved use is for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
For dosing, contraindications, adverse reactions and all clinical decisions, use the current official prescribing information and a licensed clinician. This page is an identity and sourcing guide, not medical advice.
FDA approval summary↗Why naming precision matters
A finished drug is not the same thing as an API sample.
For patients and clinicians
RASONQUE refers to the regulated, labeled prescription product. The FDA and manufacturer are the appropriate sources for product availability, prescribing information and medical inquiries.
For laboratories and developers
Daraxonrasib or RMC-6236 may describe a chemical reference, analytical material or active pharmaceutical ingredient. Suitability depends on intended use, specification, provenance and batch documentation.
For search and procurement
Include the generic name, development code and CAS number when searching, then verify whether a result is medicine, research material, a publication or a trial record before acting on it.
Primary sources
Verify at the source.
FAQ
RASONQUE and RMC-6236 questions.
Is RASONQUE the same as daraxonrasib?
RASONQUE is the U.S. brand name of the finished prescription product whose active ingredient is daraxonrasib.
Why do scientific papers call daraxonrasib RMC-6236?
RMC-6236 was the compound’s development code and remains common in publication titles, clinical-trial records and research catalogs.
What is RASolute 302?
RASolute 302 is the phase 3 study NCT06625320 that compared daraxonrasib with investigator-selected chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma.
Is Daraxon affiliated with the RASONQUE manufacturer?
No. RASONQUE is associated with Revolution Medicines. Daraxon is an independent research-material supplier and this is not the official product website.